This study evaluated the effects of alpha-s1 casein hydrolysate (ACH; Lactium®) on the\nsubjective and objective sleep profiles of a community-based sample of Koreans with poor sleep quality.\nWe performed a double-blind, randomized crossover trial with 48 participants (49.0 ....add/subs 1.7 years old,\n65% female) who exhibited a mild to moderate degree of sleep disturbance. Either ACH or placebo\nwas administered for the initial four weeks, and the counterpart was administered in precisely the\nsame manner after a four-week washout period. Sleep disturbance scales, daytime functioning,\nand psychiatric aspects showed a similar tendency to improve during both ACH and placebo\nphases without significant group differences. Overall perceived sleep profiles in sleep diaries were\nsignificantly improved during the ACH phase, represented by increased total sleep time and sleep\nefficiency (SE), as well as decreased sleep latency and wake after sleep onset (WASO). Interestingly,\nactigraphy demonstrated significantly increased SE after continuous use of ACH for four weeks,\nclearly more improved when compared to two weeks of use. The polysomnography measures\nshowed a similar tendency without statistically significant group diffierences. Our findings suggest\nthat refined ACH was well tolerated and could improve sleep quality, with possible cumulative\nbeneficial effects with long-term administration.
Loading....